Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross-sectional survey.
alcohol consumption
ayahuasca
illicit drug
psychedelic
substance use disorder
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
05
06
2021
received:
05
02
2021
accepted:
07
06
2021
pubmed:
27
7
2021
medline:
1
4
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
Emerging evidence suggests that psychedelic compounds, including the Amazonian botanical decoction ayahuasca, may provide clinical benefit in the treatment of alcohol or other drug use disorders. This study investigates associations between ayahuasca consumption in naturalistic settings and current alcohol and other drug use. Online cross-sectional study of people who have consumed ayahuasca in religious, traditional and non-traditional settings in over 40 countries. A total of 8629 participants (53% male, average age 40 years) were included in the analysis. Logistic regressions were used to explore associations between ayahuasca drinking variables and the current use of alcohol and other drugs, as well as the influence of confounding factors, such as church or community membership. The number of times ayahuasca had been consumed was strongly associated with increased odds of never or rarely drinking alcohol, never or rarely engaging in 'risky drinking' and having not consumed a range of drugs in the past month, with these effects greater for those with a prior substance use disorder compared to those without. The strength of ayahuasca drinkers subjective spiritual experience, number of personal self-insights obtained and drinking ayahuasca with an ayahuasca church were also associated with lower substance use in some models. Consumption of ayahuasca in naturalistic settings is associated with lower self-reported current consumption of alcohol and other drugs for those with and without prior substance use disorders, with such effects present after adjusting for religious or social group effects.
Substances chimiques
Hallucinogens
0
Ethanol
3K9958V90M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-274Informations de copyright
© 2021 Australasian Professional Society on Alcohol and other Drugs.
Références
Reiff CM, Richman EE, Nemeroff CB et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 2020;175:391-410.
Jerome L, Feduccia AA, Wang JB et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl) 2020;237:2485-97.
Agin-Liebes GI, Malone T, Yalch MM et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020;34:155-66.
Sessa B, Johnson MW. Can psychedelic compounds play a part in drug dependence therapy? Br J Psychiatry 2015;206:1-3.
Bogenschutz MP, Forcehimes AA. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Humanist Psychol 2016;57:389-414.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014;28:983-92.
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017;43:55-60.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29:289-99.
Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012;26:994-1002.
Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M. Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials. Front Psych 2020;10:943.
Sessa B, Sakal C, O'Brien S, Nutt D. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Rep 2019;12:e230109.
Nunes AA, Dos Santos RG, Osório FL, Sanches RF, Crippa JAS, Hallak JEC. Effects of ayahuasca and its alkaloids on drug dependence: a systematic literature review of quantitative studies in animals and humans. J Psychoactive Drugs 2016;48:195-205.
Tupper KW. The globalization of ayahuasca: harm reduction or benefit maximization? Int J Drug Policy 2008;19:297-303.
Trichter S. Ayahuasca beyond the amazon: the benefits and risks of a spreading tradition. J Transpersonal Psychology 2010;42:131-48.
Tupper KW. Ayahuasca healing beyond the Amazon: the globalization of a traditional indigenous entheogenic practice. Global Netw 2009;9:117-36.
Kavenská V, Simonová H. Ayahuasca tourism: participants in shamanic rituals and their personality styles, motivation, benefits and risks. J Psychoactive Drugs 2015;47:351-9.
Henman AR. Ayahuasca use in a religious context: The case of the União do Vegetal in Brazil 2009. Available at: https://erowid.org/chemicals/ayahuasca/ayahuasca_article2.shtml (accessed 18 January 2021).
Ference J. Balancing discretion and expansion in the União do vegetal. J Undergrad Res 2020;20:1-10.
Grob CS, McKenna DJ, Callaway JC et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 1996;184:86-94.
Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 2008;14:SR15-22.
Barbosa PCR, Tófoli LF, Bogenschutz MP et al. Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. Front Psych 2018;9:136.
Fábregas JM, González D, Fondevila S et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 2010;111:257-61.
Bouso JC, González D, Fondevila S et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PLoS One 2012;7:e42421.
Barbosa PCR, Strassman RJ, da Silveira DX et al. Psychological and neuropsychological assessment of regular hoasca users. Compr Psychiatry 2016;71:95-105.
Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol 2015;25:483-92.
Franquesa A, Sainz-Cort A, Gandy S, Soler J, Alcázar-Córcoles MÁ, Bouso JC. Psychological variables implied in the therapeutic effect of ayahuasca: a contextual approach. Psychiatry Res 2018;264:334-9.
Loizaga-Velder A, Verres R. Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence-qualitative results. J Psychoactive Drugs 2014;46:63-72.
Schmid JT, Jungaberle H, Verres R. Subjective theories about (self-)treatment with ayahuasca. Anthropol Conscious 2010;21:188-204.
Ross S. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am 2012;35:357-74.
Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 2013;6:30-42.
Shanon B. The antipodes of the mind: charting the phenomenology of the ayahuasca experience. New York: Oxford University Press, 2002.
Giovannetti C, Garcia Arce S, Rush B, Mendive F. Pilot evaluation of a residential drug addiction treatment combining traditional amazonian medicine, ayahuasca and psychotherapy on depression and anxiety. J Psychoactive Drugs 2020;52:472-81.
Soler J, Elices M, Franquesa A et al. Exploring the therapeutic potential of ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology (Berl) 2016;233:823-9.
Joaquim S, Matilde E, Elisabeth D-C et al. Four weekly ayahuasca sessions lead to increases in “acceptance” capacities: a comparison study with a standard 8-week mindfulness training program. Front Pharmacol 2018;9:224.
Higgins GA, Fletcher PJ. Therapeutic potential of 5-ht2c receptor agonists for addictive disorders. ACS Chem Nerosci 2015;6:1071-88.
Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:250-8.
Canal CE. Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. Handb Exp Pharmacol 2018;252:227-60.
Ly C, Greb AC, Cameron LP et al. Psychedelics promote structural and functional neural plasticity. Cell Rep 2018;23:3170-82.
Owaisat S, Raffa RB, Rawls SM. In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism. Neurosci Lett 2012;525:12-6.
Brierley DI, Davidson C. Developments in harmine pharmacology - implications for ayahuasca use and drug-dependence treatment. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:263-72.
Aricioglu-Kartal F, Kayır H, Tayfun UI. Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Life Sci 2003;73:2363-71.
Liester MB, Prickett JI. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J Psychoactive Drugs 2012;44:200-8.
Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs 2020;34:925-46.
Room R. Spirituality, intoxication and addiction: six forms of relationship. Subst Use Misuse 2013;48:1109-13.
Hartogsohn I. Constructing drug effects: a history of set and setting. Drug Science, Policy and Law 2017;3:2050324516683325.
Haijen ECHM, Kaelen M, Roseman L et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol 2018;9:897.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008;22:621-32.
Griffiths RR, Johnson MW, Richards WA et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 2018;32:49-69.
Barratt MJ, Ferris JA, Zahnow R, Palamar JJ, Maier LJ, Winstock AR. Moving on from representativeness: testing the utility of the global drug survey. Subst Abuse 2017;11:1178221817716391.
Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 2019;33:1088-101.
Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 2018;32:779-92.
Miller PG, Sønderlund AL. Using the internet to research hidden populations of illicit drug users: a review. Addiction 2010;105:1557-67.
Lucas P, Boyd S, Milloy MJ, Walsh Z. Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. Int J Drug Policy 2020;86:102963.
Griffiths R, Richards W, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006;187:268-83.
Francis LJLSH. A short index of mystical orientation (SIMO): a study among Roman Catholic priests. Pastoral Psychol 2004;53:49-51.
Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 2009;50:613-21.
Argento E, Capler R, Thomas G, Lucas P, Tupper KW. Exploring ayahuasca-assisted therapy for addiction: a qualitative analysis of preliminary findings among an indigenous community in Canada. Drug Alcohol Rev 2019;38:781-9.
Fernández X, Fábregas JM. Experience of treatment with Ayahuasca for drug addiction in the Brazilian Amazon. In: Labate BC, Cavnar C, eds. The therapeutic use of ayahuasca, Vol. 2014. Heidelberg: Springer, 2014.
Perkins D, Sarris J. Ayahuasca and childhood trauma: potential therapeutic applications. In: Labate BC, Cavnar C, eds. Ayahuasca healing & science. Switzerland: Springer Nature, 2021.
Berlowitz I, Walt H, Ghasarian C, Mendive F, Martin-Soelch C. Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. J Psychoactive Drugs 2019;51:323-34.
Lawn W, Hallak JE, Crippa JA et al. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep 2017;7:15201.
Doering-Silveira E, Grob CS, de Rios MD et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 2005;37:141-4.
World Health Organisation. Geneva: WHO; 2019. Available at: https://apps.who.int/gho/data/view.main.HWF11v (accessed 19 November 2020).
Althouse AD. Adjust for multiple comparisons? It's not that simple. Ann Thorac Surg 2016;101:1644-5.
Eggenberger P, Bürgisser M, Rossi RM, Annaheim S. Body temperature is associated with cognitive performance in older adults with and without mild cognitive impairment: a cross-sectional analysis. Front Aging Neurosci 2021;13:585904s.